Regulation of the production of plasminogen activators by bone resorption enhancing and inhibiting factors in three types of osteoblast-like cells.
Production of proteolytic enzymes by osteoblasts is considered to be important for the initiation of osteoclastic bone resorption. We examined the production of tissue-type (tPA) and urokinase-type plasminogen activator (uPA) activity by three types of osteoblast-like cells (normal rat osteoblasts, rat and human osteosarcoma cells) using a quantitative spectrophotometric assay and a qualitative gel overlay technique. All 3 types of cells released both types of PA-activity into the medium, but normal rat osteoblasts released uPA probably in an inactive form. Treatment with different concentrations of the bone resorbing factors bovine Parathyroid Hormone [1-84], synthetic human Parathyroid Hormone-Like Protein [1-34]. Prostaglandin E2, Interleukin-1 beta, Tumor Necrosis Factor alpha and 1,25-dihydroxyvitamin D3 increased in general the production of both PA's by all three cell types. However, there were differences in the relative potencies of these factors. In contrast, Transforming Growth Factor beta, which inhibits bone resorption, decreased PA-activity in osteoblast-like cells. In all three types of cells, under control as well as under stimulated conditions, a high molecular weight form of PA was demonstrated by the gel overlay technique, most likely a complex of tPA with the PA-inhibitor PAI-1. The uniform increase in production of PA's by osteoblast-like cells in response to bone resorbing factors and its decrease by TGF beta supports the notion that PA's are involved in bone resorption. The exact mechanism however, remains to be elucidated.
Hoekman
K
K
Department of Endocrinology and Metabolism, University Hospital Leiden, The Netherlands.
Löwik
C W
CW
vd Ruit
M
M
Bijvoet
O L
OL
Verheijen
J H
JH
Papapoulos
S E
SE
D000818:Animals; D001862:Bone Resorption; D002117:Calcitriol / Q000494:pharmacology; D015232:Dinoprostone / Q000494:pharmacology; D004591:Electrophoresis, Polyacrylamide Gel; D006133:Growth Substances / Q000494:pharmacology; D007375:Interleukin-1 / Q000494:pharmacology; D015850:Interleukin-6 / Q000494:pharmacology; D010006:Osteoblasts / Q000187:drug effects / Q000378:metabolism*; D012516:Osteosarcoma; D010281:Parathyroid Hormone / Q000494:pharmacology; D044162:Parathyroid Hormone-Related Protein; D010446:Peptide Fragments / Q000494:pharmacology; D010960:Plasminogen Activators / Q000096:biosynthesis*; D011506:Proteins / Q000494:pharmacology; D051381:Rats; D014407:Tumor Cells, Cultured; D014409:Tumor Necrosis Factor-alpha / Q000494:pharmacology
D006133:Growth Substances; D007375:Interleukin-1; D015850:Interleukin-6; D010281:Parathyroid Hormone; D044162:Parathyroid Hormone-Related Protein; D010446:Peptide Fragments; D011506:Proteins; D014409:Tumor Necrosis Factor-alpha; C054296:parathyroid hormone-related protein (1-34); D010960:Plasminogen Activators; D002117:Calcitriol; D015232:Dinoprostone